Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Out of specification Ide-cel for relapsed/refractory myeloma -> ORR 75.4% (95% CI, 63.1-85.2), CRR 35.4%, PFS @ 3 mos was 75.4% (if high CD137 activation (n=38)) and 81.3% (if low infused dose (n = 30)).”
Title: Idecabtagene vicleucel manufacturing and clinical value of out of specification products in relapsed and refractory MM
Authors: Surbhi Sidana, Yi Lin, Andrew J. Cowan, Paula Rodriguez-Otero, Christof Scheid, Peter J. Mueller, Connor Broussard, Peter W. Krengel, Yun Li, Romain Piault, Amy Corrao, Christine Ho, Krina K. Patel
You can read the Full Article in Blood Advances.
You can find other articles featuring Robert Orlowski on OncoDaily.
